APP and Cognitive impairment: 6E10, consistent with A16, caused cognitive deficits (Supplementary Fig. 14a, b), synapse loss (Supplementary Fig. 14c–e, g), complement activation (Supplementary Fig. 14f, h), neuroinflammation (Supplementary Fig. 15g–j) and microglial phagocytosis of PSD95 (Supplementary Fig. 16) in APP/PS1 mice, 6E10 treatment also lowered plaques and Aβ42 levels (Supplementary Fig. 15a–d), but not Aβ40 (Supplementary Fig. 15e, f) in APP/PS1 brains.